Compare iShares Russell 2000 ETF (IWM) vs TG Therapeutics Inc (TGTX) Price & Performance

IWM, the iShares Russell 2000 ETF, trades at $292.34, down 0.6% on the day. Technical indicators are mixed with a neutral overall signal, while moving averages show a bullish bias. The ETF has seen strong institutional inflows, with firms like AIA Group and Allspring Global Investments increasing their holdings significantly in Q1 2026 (SEC 13F filings, July 2026). Small-cap stocks have outperformed large-caps year-to-date, with the Russell 2000 up approximately 20% in 2026 (24/7 Wall Street, July 17, 2026).

The outlook for IWM hinges on continued small-cap strength, which is sensitive to interest rates and economic growth. While recent performance is robust, risks include higher volatility versus large-caps and potential Fed policy shifts. Analyst sentiment is divided, with some highlighting valuation concerns versus broader market ETFs.

TG Therapeutics (TGTX) trades at $53.96, down 1.6% on the day, with mixed technical signals showing a neutral overall trend. The company demonstrates strong profitability with 65.95% net income margin and 112.6% ROE, though recent earnings have missed expectations in two of the last three quarters. Positive clinical developments for Briumvi in multiple sclerosis and schizophrenia trials provide growth catalysts, while a shareholder investigation presents near-term uncertainty.

The outlook remains cautiously optimistic with 84.6% analyst buy ratings but a consensus price target of $48.50 below current levels. Key opportunities include Briumvi's expanding indications and strong revenue growth, while risks involve clinical trial outcomes, the ongoing legal investigation, and premium valuations with P/E of 19.2 and P/S of 12.6.